Secondary analysis of a phase 4 RCT in adults with chronic migraine and medication-overuse headache (602 analysed): eptinezumab plus brief education improved patient-reported headache impact, disability and quality of life vs placebo from week 4 to 12.
Secondary analysisn = 608
Tepper et al. Benefits of eptinezumab on patient-reported disease burden and health-related quality of life in adults with chronic migraine and medication-overuse headache: Results from the placebo-controlled RESOLUTION trial